Welcome to the Catalyst
Welcome to the Catalyst
02.06.11 | By
We are looking forward to becoming a more active participant in the health care conversation via our new blog.
Our goal is simple and straightforward. We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you and learn together.
Think of this post as our commitment to you.
We strive to become more open in our communications. We are interested in engaging directly with all who shape the debate from citizens to policymakers to bloggers and the media. We will stay centered on having thoughtful fact-based conversations about medicines, how they are made and how we can work together to help improve the lives of millions of patients across the globe. It is this last point that is most important. Let's work on how we can continually improve the lives of patients, together.
We'll write about our take on the value of the biopharmaceutical sector, as well as how policies and proposals might affect patient access to medicines, medical innovation and the ability of PhRMA member companies to compete here in the U.S. and around the world. Often times, understanding policies and trends that may seem complex are key to evaluating the importance of an initiative.
We'll discuss the contributions that innovative medicines make to the battle against disease and to controlling health care costs. And, we'll share our thinking about the challenges and costs of creating new medicines, testing them, seeking approval and getting them to pharmacy shelves to become available for patients.
We will seek your ideas and recommendations along the way. We know we won't agree on all topics, but we'll strive to have a worthwhile conversation.
We;ll try to avoid getting bogged down in technical terms or political and corporate jargon, but I'll bet we still do so from time to time. We'll link to verifiable sources of information and facts that help illuminate our industry and the challenges and opportunities it faces. For example, PhRMA recently released a terrific "Chart Pack" compiling great, user-friendly information about our industry such as: advances in medicine; spending and costs; appropriate use of medicines; and marketing and promotion.
None of us have all the answers, but we'll do our part to share what we know, as an industry, and ensure we hear from a range of thinking over time, inside and outside our industry.
All we ask of you is to ask questions and point to facts and information that may lead to a better, shared understanding of the issues at hand.
So, let's get started. The more we share ideas and engage in constructive dialogue, the better our chances of helping millions live longer, healthier and more productive lives.